Angiotensin-converting enzyme 2: Implications for blood pressure and kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 1, 2009, Pages 79-84

  Ingelfinger, Julie R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiotensin 1 7; Angiotensin 1 9; Angiotensin II; Angiotensin converting enzyme; Angiotensin converting enzyme 2; Renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORESCEIN; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OLMESARTAN; STREPTOZOCIN; XANTHONE 4 ACETIC ACID;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CELL LINE; DIABETIC NEPHROPATHY; DNA LIBRARY; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME REGULATION; GENE OVEREXPRESSION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; IN SITU HYBRIDIZATION; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; KIDNEY TUBULE CELL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN URINE LEVEL; QUANTITATIVE TRAIT LOCUS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SOLITARY TRACT NUCLEUS; STREPTOZOCIN DIABETES; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ENZYME ACTIVATORS; HUMANS; HYPERTENSION, RENAL; KIDNEY; KIDNEY DISEASES; PEPTIDYL-DIPEPTIDASE A;

EID: 58149247936     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32831b70ad     Document Type: Review

References (44)

1. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1-E9.
2. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensinconverting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275:33238-33243.
3. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277:14838-14843.
4. Tikellis C, Johnson Cl, Formbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41:392-397.
5. Santos RAS, Ferreira AJ, Simōes e Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)- Mas axis. Exp Physiol 2008; 93:519-527.
6. • Soler MJ, Wysocki J, Batlle D. Angiotensin-converting enzyme 2 and the kidney. Exp Physiol 2008; 93:549-556. This paper provides a very useful review of ACE2 in the kidney.
7. • Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physiology and disease. J Pathol 2007; 212:1-11. This paper provides a very useful review of ACE2 in health and disease.
8. • Alenina N, Xu P, Rentzsch B, et al. Genetically altered animal models for Mas and angiotensin-(1-7). Exp Physiol 2008; 93:528-537. Discusses the angiotensin-(1-7) pathways and their relevance to blood pressure and regulation of the vasculature.
9. • Lu C-Y, Huang H-Y, Yang T-H, et al. siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells. Eur J Clin Microbiol Infect Dis 2008; 27:709-715. Both summarizes the role of ACE2 as a cellular receptor for SARS-coronavirus and shows by siRNA targeting of ACE2 how this could be a strategy for therapy. Further, the results have implications for renal and vascular research.
10. • Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 2008; 93:543-548. This paper reviews ACE2 in terms of its roles in acute lung injury. This review should be helpful for those interested in ACE2 research in other tissues and organs.
11. 1-ERK/p38 MAP kinase pathway.
12. •• Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep 2008; 10:410-414. This is a very useful review that summarizes modulation of ACE2 expression by pharmacological means.
13. Zisman LS, Meixell GE, Bristow MR, Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 2003; 108:1679-1681.
14. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822-828.
15. • Gurley SB, Coffman TM. Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. Exp Physiol 2008; 93:538-542. Excellent summary of studies ablating ACE2 and also of physiology of ACE2.
16. • Guy JL, Lambert DW, Turner AJ, Porter KE. Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts. Exp Physiol 2008; 93:579-588. This paper examines functional expression of ACE2 in human cardiac myofibroblasts and describes coexpression of ACE and ACE2 in these cells.
17. • Der Sarkissian S, Grobe JL, Yuan L, et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008; 51:712-718. This paper demonstrates that overexpression of ACE2 protects the heart during ischemic injury.
18. •• Epelman S, Tang WH, Chen SY, et al. Detection of soluble angiotensin- converting enzyme 2 in heart failure: insights into the endogenous counterregulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008; 52:750-754. These authors have developed an assay for ACE2 and have examined it in heart failure.
19. •• Koitka A, Cooper ME, Thomas MC, Tikellis C. Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol 2008; 35:420-425. This paper is a superb review of the role of the RAS in the kidney.
20. Yamazato M, Yamazato Y, Sun C, et al. Overexpression of angiotensinconverting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 2007; 49:926-931.
21. • Zulli A, Burrell LM, Buxton BF, Hare DL ACE2 and AT4R are present in diseased human blood vessels. Eur J Histochem 2008; 52:39-44. This paper demonstrates the presence of ACE2 in human blood vessels in health and disease.
22. •• Diz Dl, Garcia-Espinosa MA, Gegick S, et al. Injections of angiotensin- converting enzyme 2 inhibitor MLN4760 into nucleus tractus solrtarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol 2008; 93:694-700. This paper shows that within the brain, in the nucleus tractus solitarius (NTS), Ang- (1-7) is locally synthesized from Ang II, and that normal sensitivity of the baroreflex control of heart rate requires this to respond to hypertension.
23. •• Feng Y, Yue X, Xia H, et al. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin ll-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Research 2008; 102:729-736. This paper shows that overexpressing ACE2 in the subfornical organ of the brain prevented the angiotensin ll-mediated pressor and drinking responses.
24. • Ji H, Menini S, Zheng W, et al. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17 beta-oestradiol regulation of renal pathology in renal wrap hypertension. Exp Physiol 2008; 93:648-657. This paper shows that 17-beta estradiol both increases ACE2 protein and prevents tubular and glomerular injury in the renal wrap hypertension model.
25. Benjafield AV, Wang WY, Morris BJ. No association of angiotensin- converting enzyme gene (ACE2) polymorphisms with hypertension. Am J Hypertens 2004; 17:624-628.
26. Lieb W, Graf J, Gotz A, et al. Association of angiotensin- converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiography substudy. J Mol Med 2006; 84:88-96.
27. Huang W, Yang W, Wang Y, et al. Association of angiotensin-converting enzyme gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese. J Hum Hypertens 2006; 20:968-971.
28. Zhong J, Yan Z, Liu D, et al. Association of angiotensin- converting enzyme gene (ACE2) A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. J Lab Clin Med 2006; 147:91-95.
29. Niu W, Qi YS, Zhou W, Qui C. Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in Han Chinese. Translational Res 2007; 150:374-380.
30. • Sluimer JC, Gasc JM, Hamming I, et al. Angiotensin- converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol 2008; 215:273-279. These authors examined ACE2 expression and activity in human carotid lesions, observing that expression varies with the extent of disease.
31. • Igase M, Kohara K, Nagai T, et al. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res 2008; 31:553-559. This paper indicates that ACE2 is regulated by factors other than blood pressure in the SHR.
32. • Dong B, Zhang C, Feng JB, et al. Over-expression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28:1270-1276. These authors used a rabbit model of atherosclerosis to show that overexpression of ACE2 may help to stabilize atherosclerotic plaques.
33. Shaltout HA, Westwood BM, Averill DB. et al. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2dependent processing of angiotensin II. Am J Physiol Renal Physiol 2007; 292:F82-F91.
34. Lely AT, Hamming I, van Goor H, Navis GJ. Renal ACE2 expression in human kidney disease. J Pathol 2004; 204:587-593.
35. Ye M, Wysocki J, William J, et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17:3067-3075; doi: 10.1681.
36. • Tikellis C, Bialkowski K, Pete J, et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008; 57:1018-1025. This study indicates that diabetes modifies ACE2 expression, which influences the development of renal injury and responsiveness to blocking ACE2.
37. Soler MJ, Wysocki J, Ye M, et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007; 72:614-623.
38. Wong DW, Oudit GY, Reich H, et al. Loss of angiotensin-converting enzyme- 2 accelerates diabetic kidney injury. Am J Pathol 2007; 171:438-451.
39. Shao Y, He M, Zhou L, et al. Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta Pharmacol Sin 2008; 29:829-837.
40. • Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008; 51:613-623. This study compares ACE and ACE2 expression in kidneys of normal subjects and in those with diabetes. They conclude that the high ACE/ACE2 ratio in the kidneys of patients with type 2 diabetes may contribute to renal injury.
41. • Wang G, Lai FM-M, Lai K-B, et al. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia 2008; 51:1062-1067. This study showed that urinary expression of ACE2 mRNA correlated with proteinuria.
42. •• Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identi-fication of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 51:1312-1317. This study suggests that ACE2 activators may be useful as a strategy to treat hypertension.
43. 1' subsite. Bioorganic Med Chem Lett 2008; 18:1681-1687. This study explores potential ACE2 inhibitors.
44. • Lew RA, Warner FJ, Hanchapola I, et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008; 93:685-693. This study demonstrates that an endogenous inhibitor may mask ACE2 activity in human plasma.